Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 201 to 210 of 276 total matches.

Ertugliflozin for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
with an eGFR ...
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan). Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Med Lett Drugs Ther. 2018 Apr 23;60(1545):70-2 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
conduction disorders, or heart failure. Use of the drug should be avoided in patients with congenital long ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
-site reactions ▶ Increased heart rate ▶ Renal impairment and acute renal failure ▶ Possible ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-3   doi:10.58347/tml.2024.1708c |  Show IntroductionHide Introduction

Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
with heart failure, renal impairment, or electrolyte disturbances is unknown. Sodium phosphate tablets ...
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik, which is supplied as a powder for reconstitution.
Med Lett Drugs Ther. 2018 May 21;60(1547):84-6 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer

   
Treatment Guidelines from The Medical Letter • Mar 01, 2003  (Issue 7)
erythrodysesthesia; conjunctivitis; heart failure; seizures Flutamide (Eulexin – Schering; Nausea; diarrhea; hot ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Treat Guidel Med Lett. 2003 Mar;1(7):41-52 |  Show IntroductionHide Introduction

Pipecuronium - A New Neuromuscular Blocker

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990  (Issue 833)
patients and in those with renal failure (JE Caldwell et al, Anesthesiology, 70:7, 1989). The advantage ...
Pipecuronium bromide (Arduan - Organon), a long-acting, non-depolarizing neuromuscular agent chemically related to pancuronium (Pavulon; and others), is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. It is not recommended for procedures that last less than 90 minutes or for patients requiring prolonged mechanical ventilation in intensive care units.
Med Lett Drugs Ther. 1990 Dec 14;32(833):114 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
reactions, new-onset psoriasis, cytopenias, nonischemic congestive heart failure, demyelinating disorders ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Substituting For Cerivastatin (Baycol)

   
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001  (Issue 1113)
in creatinine kinase, rarely progressing to rhabdomyolysis, myoglobinemia and renal failure, have occurred ...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Med Lett Drugs Ther. 2001 Sep 17;43(1113):79-80 |  Show IntroductionHide Introduction

In Brief: Casgevy for Beta Thalassemia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
thalassemia. THE DISORDER — Beta thalassemia can cause severe anemia, fatigue, shortness of breath, failure ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia. Casgevy is the first gene therapy that uses CRISPR/Cas9 gene-editing technology to be approved in the US for any disorder. Betibeglogene autotemcel (Zynteglo), an autologous lentiviral vector cell-based gene therapy, was approved in the US in 2022 for treatment of transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79   doi:10.58347/tml.2024.1702d |  Show IntroductionHide Introduction

A Percutaneous Device (MitraClip) for Mitral Regurgitation

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
regurgitation, but it generally involves open heart surgery and cardiopulmonary bypass and can cause ...
The FDA has approved the use of a transcatheter mitral valve device (MitraClip – Abbott) for percutaneous treatment of significant symptomatic degenerative mitral regurgitation (grade 3-4+) in patients who are at prohibitive risk for mitral valve surgery. It is the first percutaneous nonsurgical treatment approved for this indication.
Med Lett Drugs Ther. 2013 Dec 23;55(1432):103-4 |  Show IntroductionHide Introduction